| アブストラクト | BACKGROUND: Postmarketing reports suggest that finasteride causes sexual dysfunction despite a low incidence reported in clinical trials. Therefore, the extent of risk remains unknown. OBJECTIVE: To determine whether the risk of sexual dysfunction is higher among individuals treated with finasteride compared to a baseline risk for all other drugs using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database. METHODS: A case by non-case disproportionality approach was used whereby a reporting odds ratio (ROR) with 95% confidence interval (CI) was calculated. The National Ambulatory Medical Care Survey (NAMCS) was used to confirm results. RESULTS: A significant disproportionality in reporting of sexual dysfunction with the use of finasteride was observed whether finasteride was indicated for hair loss (ROR = 138.17, 95% CI: 133.13, 143.4), prostatic hyperplasia (ROR = 93.88, 95% CI: 84.62, 104.16) or any indication (ROR = 173.18, 95% CI: 171.08, 175.31). When these results were stratified by age, disproportionality was strongest at 31-45 years. CONCLUSION: Use of finasteride has led to an increase in reports of sexual dysfunction where it is believed to be the primary suspect. |
|---|
| ジャーナル名 | Journal of the European Academy of Dermatology and Venereology : JEADV |
|---|
| Pubmed追加日 | 2017/03/17 |
|---|
| 投稿者 | Gupta, A K; Carviel, J; MacLeod, M A; Shear, N |
|---|
| 組織名 | Department of Medicine, University of Toronto School of Medicine, Toronto, ON,;Canada.;Mediprobe Research Inc., London, ON, Canada.;Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences;Centre, University of Toronto, Toronto, ON, Canada. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/28300347/ |
|---|
